美国 · SEC FORM 4
Lipocine Inc.
LPCN · Nasdaq · CIK 0001535955 · Healthcare · Biotechnology
内部人信号
1 位买方 · 3 条买入交易行 · $82.2K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ✓ 角色得分高 · 买入者中职位最高的是：Director
- ✓ Recent activity · latest purchase 2026-09-30
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 52.1
- 51.9
- 51.7
- 51.6
- 51.3
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -23.6%
- 3M
- -26.8%
- 6M
- -21.8%
- 12M
- -45.6%
波动率与流动性
- 波动率
- 89.6%
- Beta
- —
- 平均每日成交额
- USD 3.0M
估值
- 市值
- USD 14.2M
- P/E
- —
基本面
- 利润率
- -487.2%
- ROE
- -66.5%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, 利润率, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-03 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 97,816
- 上期报告
- 99,444
- 日均成交量
- 43,279
- 回补天数
- 2.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Higuchi John W. | 买入 (P) | Common stock | 15,970 | USD 2.23 | USD 35,613 | SEC 申报 ↗ |
| 2026-09-29 | Higuchi John W. | 买入 (P) | Common stock | 9,037 | USD 2.15 | USD 19,430 | SEC 申报 ↗ |
| 2026-09-28 | Higuchi John W. | 买入 (P) | Common stock | 12,561 | USD 2.16 | USD 27,132 | SEC 申报 ↗ |
| 2026-04-07 | Higuchi John W. | 买入 (P) | Common stock | 40,000 | USD 2.03 | USD 81,200 | SEC 申报 ↗ |
| 2026-04-06 | Patel Mahesh V. | 买入 (P) | Common stock | 25,000 | USD 2.03 | USD 50,750 | SEC 申报 ↗ |
| 2026-04-06 | Higuchi John W. | 买入 (P) | Common stock | 123,000 | USD 2.05 | USD 252,150 | SEC 申报 ↗ |
| 2026-04-02 | Patel Mahesh V. | 买入 (P) | Common stock | 25,000 | USD 2.02 | USD 50,500 | SEC 申报 ↗ |
| 2023-05-25 | Patel Mahesh V. | 买入 (P) | Common Stock | 8,706 | USD 5.03 | USD 43,791 | SEC 申报 ↗ |
| 2023-03-24 | Patel Mahesh V. | 买入 (P) | Common Stock | 150,000 | USD 0.32 | USD 48,000 | SEC 申报 ↗ |
| 2023-03-20 | Ono Richard Dana | 买入 (P) | Common Stock | 4,000 | USD 0.34 | USD 1,360 | SEC 申报 ↗ |
| 2023-03-17 | Patel Mahesh V. | 买入 (P) | Common Stock | 50,000 | USD 0.33 | USD 16,500 | SEC 申报 ↗ |
| 2022-11-22 | Papapetropoulos Spyros | 买入 (P) | Common stock | 21,739 | USD 0.47 | USD 10,217 | SEC 申报 ↗ |
| 2022-11-14 | Patel Mahesh V. | 买入 (P) | Common Stock | 75,000 | USD 0.39 | USD 29,250 | SEC 申报 ↗ |
| 2022-09-27 | Patel Mahesh V. | 买入 (P) | Common Stock | 100,000 | USD 0.41 | USD 41,000 | SEC 申报 ↗ |
| 2022-05-17 | Fogarty Krista | 买入 (P) | Common Stock | 12,500 | USD 0.86 | USD 10,750 | SEC 申报 ↗ |
Form 4 申报证据
7 transaction lines in the latest 365-day window; 36 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Higuchi John W. | 买入 (P) | Common stock | 15,970 | USD 2.23 | USD 35,613 | SEC 申报 ↗ |
| 2026-09-29 | Higuchi John W. | 买入 (P) | Common stock | 9,037 | USD 2.15 | USD 19,430 | SEC 申报 ↗ |
| 2026-09-28 | Higuchi John W. | 买入 (P) | Common stock | 12,561 | USD 2.16 | USD 27,132 | SEC 申报 ↗ |
展开近期 Form 4 证据 (7 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Higuchi John W. | 买入 (P) | Common stock | 15,970 | USD 2.23 | USD 35,613 | SEC 申报 ↗ |
| 2026-09-29 | Higuchi John W. | 买入 (P) | Common stock | 9,037 | USD 2.15 | USD 19,430 | SEC 申报 ↗ |
| 2026-09-28 | Higuchi John W. | 买入 (P) | Common stock | 12,561 | USD 2.16 | USD 27,132 | SEC 申报 ↗ |
| 2026-04-07 | Higuchi John W. | 买入 (P) | Common stock | 40,000 | USD 2.03 | USD 81,200 | SEC 申报 ↗ |
| 2026-04-06 | Patel Mahesh V. | 买入 (P) | Common stock | 25,000 | USD 2.03 | USD 50,750 | SEC 申报 ↗ |
| 2026-04-06 | Higuchi John W. | 买入 (P) | Common stock | 123,000 | USD 2.05 | USD 252,150 | SEC 申报 ↗ |
| 2026-04-02 | Patel Mahesh V. | 买入 (P) | Common stock | 25,000 | USD 2.02 | USD 50,500 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | LPCN |
| CIK | 0001535955 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 36 transaction lines from 2020-03-17 to 2026-09-30 18 P purchase lines · 6 S sale lines · 12 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.